OR-AIRSHIP
27.10.2021 15:02:16 CEST | Business Wire | Press release
Later today at Elevate 2021 , the mobile app experience company Airship will debut its next-generation App Experience Platform that makes it simple to create, measure and perfect in-app experiences crucial to onboarding app audiences, building user understanding for next-level personalization, and advancing monetization goals through a data-led approach. New innovations including Airship Tours, Airship Surveys and Airship Preference Center, give business users full control to easily create, automate and adapt rich, native app experiences for continuous onboarding and first-party and zero-party data collection without ongoing developer support or having to update apps in the App Store or Google Play.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211027005301/en/
“Mobile apps have become the preferred destination for customers due to simple, contextual interactions, faster transactions and streamlined experiences that elegantly span their digital and physical worlds, like click-and-collect, loyalty and subscription programs, and direct-to-consumer commerce to name a few,” said Brett Caine, CEO and president, Airship. “However, realizing the full business potential of apps is challenging with progress hampered by reliance on development resources and cyclical app updates that have left marketers, and the industry-at-large, approaching apps as another promotional channel rather than creating reciprocal value exchanges necessary for sustained relationships.”
Mobile app retention rates average only 28 percent after day one and 15 percent after the first week1 , yet app users produce 3.5X more revenue than other shoppers and they are 3X more likely to make a repeat purchase2 . First impressions are critical, and Airship Tours allows marketers and mobile product owners to easily create, edit and manage full-screen, interactive walkthroughs (up to 10 screens long) that showcase the value of the app and how to get started. Tours can drive onboarding, feature adoption, loyalty enrollment or any number of key milestone activities such as completing their profile, authenticating within the app, opting into notifications, setting preferences and more. Tours can be triggered based on customers’ real-time behaviors and attributes, enabling exceptionally relevant and personalized treatments, and real-time analytics that highlight ways to improve the experience and outcomes.
Airship Surveys allow marketers and mobile product owners to collect granular feedback from users while they are engaged with the app, gaining actionable insights to improve app experiences without developer involvement. Surveys can be targeted to customers based on their attributes and real-time behaviors, such as purchases, engagement with a new feature, abandoned carts or Tours completed, and resulting data can be analyzed by customer segments for more nuanced understanding and to target future campaigns. Pre-built survey templates for NPS and product feedback make it easy to get started.
Announced last month, Airship Preference Center now encompasses all re-engagement messaging channels (e.g., SMS and email), enabling customers to control the types of content they receive on different channels in one place. Marketers and mobile product owners can also take advantage of opt-in forms for SMS and email to place on their websites, and can see all channels a user has opted in to from lookups within the Airship App Experience Platform.
Availability
These new solutions will be available over the coming months. Brands interested in getting first access can request to join Airship’s special access program .
Airship is a Leader in “The Forrester Wave™: Mobile Engagement Automation, Q3 2020 ,” receiving the highest score in the Strategy category and the second highest score in the Current Offering category.
About Airship
No one knows more, does more, or cares more when it comes to helping brands master mobile app experiences than Airship. From the beginning of apps, we powered the first commercial messages and then expanded our data-led approach to all re-engagement channels (mobile wallet, SMS, email), app UX experimentation, proactive in-app conversations and now rich in-app experiences that business users can create and adapt on their own — with no ongoing developer support or app update required.
From the trillions of mobile app interactions we’ve powered for thousands of global brands, we’ve been there, and done that, lending our solutions and expertise to help apps become the pinnacle of elegant customer experiences and winning brand loyalty strategies. One could say Airship has one mission: to go where mobile will take your business.
For more information, visit www.airship.com , read our blog or follow us on Twitter , LinkedIn and Facebook .
1
Adjust "Mobile App Trends 2021: A Global Benchmark of App Performance"
2
eMarketer, “Frictionless Commerce,” May 21, 2020
View source version on businesswire.com: https://www.businesswire.com/news/home/20211027005301/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom